Tags

Type your tag names separated by a space and hit enter

Tocilizumab in COVID-19: Beware the risk of intestinal perforation.
Int J Antimicrob Agents. 2020 Jul; 56(1):106009.IJ

Authors+Show Affiliations

Clinical Immunology Unit, Stavanger University Hospital, Stavanger, Norway.Cardiac Intensive Care Unit, Cincinnati Children's Hospital Medical Center, Ohio, USA. Electronic address: brandon.henry@cchmc.org.

Pub Type(s)

Letter

Language

eng

PubMed ID

32389721

Citation

Vikse, Jens, and Brandon Michael Henry. "Tocilizumab in COVID-19: Beware the Risk of Intestinal Perforation." International Journal of Antimicrobial Agents, vol. 56, no. 1, 2020, p. 106009.
Vikse J, Henry BM. Tocilizumab in COVID-19: Beware the risk of intestinal perforation. Int J Antimicrob Agents. 2020;56(1):106009.
Vikse, J., & Henry, B. M. (2020). Tocilizumab in COVID-19: Beware the risk of intestinal perforation. International Journal of Antimicrobial Agents, 56(1), 106009. https://doi.org/10.1016/j.ijantimicag.2020.106009
Vikse J, Henry BM. Tocilizumab in COVID-19: Beware the Risk of Intestinal Perforation. Int J Antimicrob Agents. 2020;56(1):106009. PubMed PMID: 32389721.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Tocilizumab in COVID-19: Beware the risk of intestinal perforation. AU - Vikse,Jens, AU - Henry,Brandon Michael, Y1 - 2020/05/07/ PY - 2020/04/06/received PY - 2020/04/08/accepted PY - 2020/5/12/pubmed PY - 2020/8/5/medline PY - 2020/5/12/entrez SP - 106009 EP - 106009 JF - International journal of antimicrobial agents JO - Int J Antimicrob Agents VL - 56 IS - 1 SN - 1872-7913 UR - https://www.unboundmedicine.com/medline/citation/32389721/Tocilizumab_in_COVID_19:_Beware_the_risk_of_intestinal_perforation_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S0924-8579(20)30167-9 DB - PRIME DP - Unbound Medicine ER -